July/August 2016

The Impact of Rare Diseases and Drug Therapy

August 18, 2016

Specialty Healthcare Benefits Council

The development and implementation of a rare disease management program by healthcare providers and payors could greatly assist in improving the clinical, psycho-social and economic impacts for this patient population.

Private-payer Costs for Employees with Treatment-resistant Depression

August 18, 2016

Original Research

Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.

Factors Associated with Zostavax Abandonment

August 18, 2016

Original Research

This study highlights the implications of noncompliance with the use of in-network providers for immunization services, shedding light on value-based benefits design to promote access to recommended vaccinations.